1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Alnylam Pharmaceuticals Inc (ALNY) Files 10-K for the Fiscal Year Ended on December 31, 2019

February 13, 2020 | About:

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes. Alnylam Pharmaceuticals Inc has a market cap of $14.6 billion; its shares were traded at around $130.10 with and P/S ratio of 82.29. GuruFocus has detected 6 severe warning signs with Alnylam Pharmaceuticals Inc. .

For the last quarter Alnylam Pharmaceuticals Inc reported a revenue of $71.7 million, compared with the revenue of $21.03 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $219.8 million, an increase of 193.4% from last year. For the complete 30-year financial data, please go here.. For the last five years Alnylam Pharmaceuticals Inc had an average revenue growth rate of 32.3% a year.

The reported loss per diluted share was $8.11 for the year, compared with the loss per share of $4.79 in the previous year. The Alnylam Pharmaceuticals Inc had an operating margin of -427.5%, compared with the operating margin of -1087.56% a year before. The 10-year historical median operating margin of Alnylam Pharmaceuticals Inc is -280.70%. The profitability rank of the company is 2 (out of 10).

At the current stock price of $130.10, Alnylam Pharmaceuticals Inc is traded at close to its historical median P/S valuation band of $122.45. The P/S ratio of the stock is 82.29, while the historical median P/S ratio is 77.45. The stock gained 54.17% during the past 12 months.

Directors and Officers Recent Trades:

  • Director Phillip A Sharp sold 30,000 shares of ALNY stock on 02/12/2020 at the average price of $130. The price of the stock has increased by 0.08% since.
  • Director Steven M Paul sold 30,000 shares of ALNY stock on 02/10/2020 at the average price of $130. The price of the stock has increased by 0.08% since.
  • EVP, Chief Legal Officer Laurie Keating sold 10,000 shares of ALNY stock on 02/10/2020 at the average price of $129. The price of the stock has increased by 0.85% since.
  • COO Yvonne Greenstreet sold 16,142 shares of ALNY stock on 02/10/2020 at the average price of $127.64. The price of the stock has increased by 1.93% since.
  • President, R&D Akshay Vaishnaw sold 23,708 shares of ALNY stock on 02/07/2020 at the average price of $125. The price of the stock has increased by 4.08% since.

For the complete 20-year historical financial data of ALNY, click here.


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
/* */